CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the chief in precision genetic drugs for uncommon illnesses, granted fairness awards on October 31, 2022 that have been beforehand permitted by the Compensation Committee of its Board of Directors beneath Sarepta’s 2014 Employment Commencement Incentive Plan, as a cloth inducement to employment to 34 people employed by Sarepta in October 2022. The fairness awards have been permitted in accordance with Nasdaq Listing Rule 5635(c)(4).
The staff obtained, within the mixture, choices to buy 31,125 shares of Sarepta’s frequent inventory, and within the mixture 16,075 restricted inventory items (“RSUs”). The choices have an train value of $114.02 per share, which is the same as the closing value of Sarepta’s frequent inventory on October 31, 2022 (the “Grant Date”). One-fourth of the shares underlying every worker’s possibility will vest on the one-year anniversary of the Grant Date and thereafter 1/forty eighth of the shares underlying every worker’s possibility will vest month-to-month, such that the shares underlying the choice granted to every worker shall be absolutely vested on the fourth anniversary of the Grant Date, in every case, topic to every such worker’s continued employment with Sarepta on such vesting dates.
One-fourth of the RSUs will vest yearly on every anniversary of the Grant Date, such that the RSUs granted to every worker shall be absolutely vested on the fourth anniversary of the Grant Date, in every case, topic to every such worker’s continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is on an pressing mission: engineer precision genetic drugs for uncommon illnesses that devastate lives and lower futures brief. We maintain management positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we presently have greater than 40 packages in varied phases of growth. Our huge pipeline is pushed by our multi-platform Precision Genetic Medicine Engine in gene remedy, RNA and gene modifying. For extra data, please go to www.sarepta.com or observe us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely put up data which may be essential to traders within the ‘For Investors’ part of our web site at www.sarepta.com. We encourage traders and potential traders to seek the advice of our web site commonly for essential details about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
Ian Estepan, 617-274-4052
[email protected]
Media Contact:
Tracy Sorrentino, 617-301-8566
[email protected]
